On March 15, 2023 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that the Company will be presenting two posters at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place in Orlando, April 14-19 (Press release, Kintara Therapeutics, MAR 15, 2023, View Source [SID1234628786]). The presentation will include data from its lead program, VAL-083, for the treatment of recurrent glioblastoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data presentations:

Session Title: Late-Breaking Research: Clinical Research 1 / Endocrinology
Poster Section: 34
Presentation Time: Monday, April 17, 2023 – 1:30 to 5:00 p.m. ET

Title: RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access – case reports
Abstract Number: LB126
Title: VAL-083 in patients with recurrent glioblastoma treated under expanded access program
Abstract Number: LB127
Abstracts are currently available on the AACR (Free AACR Whitepaper) website. A copy of the presentations will also be available after the closure of the meeting on April 19, under the Publications and Abstracts tab of the News & Media section of the Company’s website.